Avandaryl

Avandaryl is a brand name of glimepiride/rosiglitazone, approved by the FDA in the following formulation(s):

AVANDARYL (glimepiride; rosiglitazone maleate - tablet; oral)

• 
  Manufacturer: SB PHARMCO
  
  Approval date: November 23, 2005
  
  Strength(s): 1MG;4MG ^[RLD], 2MG;4MG, 4MG;4MG
  


• 
  Manufacturer: SB PHARMCO
  
  Approval date: March 30, 2007
  
  Strength(s): 2MG;8MG, 4MG;8MG
  

Has a generic version of Avandaryl been approved?

No. There is currently no therapeutically equivalent version of Avandaryl available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avandaryl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Novel compounds
  Patent 5,002,953
  Issued: March 26, 1991
  Inventor(s): Hindley; Richard M.
  Assignee(s): Beecham Group p.l.c.
  Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
  
  Patent expiration dates:
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: TREATMENT FOR TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 17, 2012
    
    ✓ 
    Patent use: FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
    ✓ 
    Pediatric exclusivity
  
  
  
  • March 17, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Substituted thiazolidinedionle derivatives
  Patent 5,741,803
  Issued: April 21, 1998
  Inventor(s): Pool; Colin Ripley & Tremper; Alan William & Brightwell; Malcolm David & Roman; Robin Sherwood
  Assignee(s): SmithKline Beecham plc
  ##STR1## A compound of formula (I) or a tautomeric form therof and/or a pharmaceutically acceptable solvate thereof, wherein R1,A1,A2,M are as defined in the, specification. A process for preparing such a compound, a pharmaceutical composition containin such a compound and the use of such a compound for treating hyperglycemia.
  
  Patent expiration dates:
  
  
  • April 21, 2015
    
    ✓ 
    Patent use: TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • April 21, 2015
    
    ✓ 
    Patent use: FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 21, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Thiazolidinedione derivative and its use as antidiabetic
  Patent 7,358,366
  Issued: April 15, 2008
  Inventor(s): Blackler; Paul David James & Giles; Robert Gordon & Moore; Stephen & Sasse; Michael John
  Assignee(s): SmithKline Beecham p.l.c.
  A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
  
  Patent expiration dates:
  
  
  • April 19, 2020
    
    ✓ 
    Drug substance
  
  
  
  • October 19, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Avandaryl Consumer Information (Drugs.com)
• Avandaryl Consumer Information (Wolters Kluwer)
• Avandaryl Consumer Information (Cerner Multum)
• Avandaryl Advanced Consumer Information (Micromedex)
• Glimepiride/Rosiglitazone Consumer Information (Wolters Kluwer)
• Glimepiride and rosiglitazone Consumer Information (Cerner Multum)
• Glimepiride and rosiglitazone Advanced Consumer Information (Micromedex)
• Rosiglitazone and glimepiride Advanced Consumer Information (Micromedex)